Sterling Capital Management’s Generate Biomedicines GENB Stock Holding History

Sterling Capital Management’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.58K	Buy	+212	New	+$2.89K	﹤0.01%	2785

Other funds holding GENB

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Sterling Capital Management's GENB Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Generate Biomedicines (GENB) in Q2 2026: 212 shares worth $3.58K. The stake represents ﹤0.01% of the portfolio and ranks #2785 among its holdings.

12 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Sterling Capital Management held 212 shares of Generate Biomedicines worth $3.58K as of Q2 2026.
Generate Biomedicines was a new Sterling Capital Management position in Q2 2026.
Generate Biomedicines made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2785 holding.
12 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.